Gas chromatographic analysis of dimethyltryptamine and β-carboline alkaloids in Ayahuasca, an amazonian psychoactive plant beverage

Phytochemical Analysis

Volumn 20, Issue 2, 2009, Pages 149-153

  Pires, Ana Paula Salum ^a   De Oliveira, Carolina Dizioli Rodrigues ^a   Moura, Sidnei ^a   Dörr, Felipe Augusto ^a   Silva, Wagner Abreu E ^a   Yonamine, Mauricio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Ayahuasca; Dimethyltryptamine; Gas chromatography; carbolines

Indexed keywords

CHROMATOGRAPHIC ANALYSIS; GAS CHROMATOGRAPHY; GASES; GASOLINE; METABOLITES; PHASE SEPARATION; PLANTS (BOTANY);

ACTIVE CONSTITUENTS; AYAHUASCUM; CARBOLINES; CHROMATOGRAPHIC METHODS; DIMETHYLTRYPTAMINE; GAS-CHROMATOGRAPHIC ANALYSIS; IN COMPOSITIONS; MONOAMINE OXIDASE INHIBITORS; SIMULTANEOUS DETERMINATIONS; Β-CARBOLINE;

ALKALOIDS;

ALKALOID; BETA CARBOLINE; HARMALINE; HARMINE; INDOLE; MONOAMINE OXIDASE INHIBITOR; N,N DIMETHYLTRYPTAMINE; NITROGEN; PHOSPHORUS; PSYCHEDELIC AGENT; CARBOLINE DERIVATIVE;

ARTICLE; AYAHUASCA; BANISTERIOPSIS; BEVERAGE; CHEMICAL COMPOSITION; CONTROLLED STUDY; GAS CHROMATOGRAPHY; PLANT LEAF; PLANT STEM; PSYCHOTRIA; SOLID PHASE EXTRACTION; SOUTH AMERICA; VALIDATION PROCESS; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD;

ANIMALIA; BANISTERIOPSIS CAAPI; PSYCHOTRIA VIRIDIS;

ALKALOIDS; BANISTERIOPSIS; BEVERAGES; CARBOLINES; CHROMATOGRAPHY, GAS; MAGNETIC RESONANCE SPECTROSCOPY; N,N-DIMETHYLTRYPTAMINE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 65249140694     PISSN: 09580344     EISSN: 10991565     Source Type: Journal    
DOI: 10.1002/pca.1110     Document Type: Article

References (14)

1. Armbruster DA, Tillman MD and Hubbs LM. 1994. Limit of detection (LOD)/ limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs. Clin Chem 40: 1233-1238.
2. Conselho Nacional Antidrogas Brasil. Resolução no. 4, de 4 de novembro de 2004. Diário Oficial da União (DOU) da República Federativa do Brasil, 8 de novembro de 2004.
3. Callaway JC. 2005. Fast and slow metabolizers of Hoasca. J Psychoactive Drugs 37: 157-161.
4. Callaway JC, Raymon LP, Hearn WL, McKenna DJ, Grob CS, Brito GS and Mash DC. 1996. Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca. J Anal Toxicol 20: 492-497.
5. Callaway JC, McKenna DJ, Grob CS, Brito GS, Raymon LP, Poland RE, Andrade EO and Mash DC. 1999. Pharmacokinectics of Hoasca alkaloids in healthy humans. J. Ethnopharmacol 65: 243-256.
6. Gable RS. 2007. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction 102: 24-34.
7. Giumanini AG, Chiavari G, Musiani MM and Rossi P. 1980. N-permethylation of primary and secondary aromatic amines. Synthesis 743-745.
8. Kikura-Hanajiri R, Hayashi K, Saisho K and Goda Y. 2005. Simultaneous determination of nineteen hallucinogenic tryptamines/β-carbolines and phenethylamines using gas chromatography-mass spectrometry and liquid chromatography-electrospray ionization-mass spectrometry. J Chromatogr B 825: 29-37.
9. McKenna DJ. 2004. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther 102: 111-129.
10. McKenna DJ, Towers GHN and Abbott FS. 1984. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca. J. Ethnopharmacol 10: 195-223.
11. Riba J and Barbanoj MJ. 2005. Bringing ayahuasca to the clinical research laboratory. J Psychoactive Drugs 37: 219-230.
12. Riba J, Rodríguez-Fornells A, Urbano G, Morte A, Antonijoan R, Montero M, Callaway JC and Barbanoj MJ. 2001. Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers. Psychopharmacology 154: 85-95.
13. Riba J, Valle M, Urbano G, Yritia M, Morte A and Barbanoj MJ. 2003. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excrection, and pharmacokinetics. J Pharmacol Exp Ther 306: 73-83.
14. Yritia M, Riba J, Ortuño J, Ramirez A, Castillo A, Alfaro Y, De La Torre R and Barbanoj MJ. 2002. Determination of N,N-dimethyltryptamine and β-carboline alkaloids in human plasma following oral administration of ayahuasca. J Chromatogr B 779: 271-281.